Stock Track | Blueprint Medicines Plummets 8.27% as Q4 Earnings Miss Overshadows Revenue Beat

Stock Track

13 Feb

Blueprint Medicines Corp. (BPMC) saw its stock plummet 8.27% in pre-market trading on Thursday, after the company reported its fourth-quarter and full-year 2024 financial results.

The biopharmaceutical company, focused on developing treatments for cancer and rare diseases, reported mixed results for the quarter:

Earnings: Q4 GAAP EPS of $(0.79) missed the analyst consensus estimate of $(0.70) by 12.86%.
Revenue: Q4 revenue of $146.37 million beat the analyst consensus estimate of $145.84 million by 0.36%. This represented a 103.41% increase from the same period last year.

For the full year 2024, Blueprint Medicines reported:

Revenue: $508.8 million, including $479.0 million in net product revenue from its lead drug AYVAKIT/AYVAKYT.
Net Loss: $67.1 million, or $(1.07) per share.

The company provided guidance for 2025, anticipating global AYVAKIT net product revenue of approximately $680 million to $710 million, representing 45% year-over-year growth at the midpoint.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1140978482"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1140978482\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1140978482?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-13 22:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140978482","market":"hk","top_or_hot":-1,"title":"Stock Track | Blueprint Medicines Plummets 8.27% as Q4 Earnings Miss Overshadows Revenue Beat","media":"Stock Track","content":"<p>Blueprint Medicines Corp. (BPMC) saw its stock plummet 8.27% in pre-market trading on Thursday, after the company reported its fourth-quarter and full-year 2024 financial results.</p>\n\n<p>The biopharmaceutical company, focused on developing treatments for cancer and rare diseases, reported mixed results for the quarter:</p>\n<ul>\n<li>Earnings: Q4 GAAP EPS of $(0.79) missed the analyst consensus estimate of $(0.70) by 12.86%.</li>\n<li>Revenue: Q4 revenue of $146.37 million beat the analyst consensus estimate of $145.84 million by 0.36%. This represented a 103.41% increase from the same period last year.</li>\n</ul>\n\n<p>For the full year 2024, Blueprint Medicines reported:</p>\n<ul>\n<li>Revenue: $508.8 million, including $479.0 million in net product revenue from its lead drug AYVAKIT/AYVAKYT.</li>\n<li>Net Loss: $67.1 million, or $(1.07) per share.</li>\n</ul>\n\n<p>The company provided guidance for 2025, anticipating global AYVAKIT net product revenue of approximately $680 million to $710 million, representing 45% year-over-year growth at the midpoint.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Blueprint Medicines Plummets 8.27% as Q4 Earnings Miss Overshadows Revenue Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Blueprint Medicines Plummets 8.27% as Q4 Earnings Miss Overshadows Revenue Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-13 22:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Blueprint Medicines Corp. (BPMC) saw its stock plummet 8.27% in pre-market trading on Thursday, after the company reported its fourth-quarter and full-year 2024 financial results.</p>\n\n<p>The biopharmaceutical company, focused on developing treatments for cancer and rare diseases, reported mixed results for the quarter:</p>\n<ul>\n<li>Earnings: Q4 GAAP EPS of $(0.79) missed the analyst consensus estimate of $(0.70) by 12.86%.</li>\n<li>Revenue: Q4 revenue of $146.37 million beat the analyst consensus estimate of $145.84 million by 0.36%. This represented a 103.41% increase from the same period last year.</li>\n</ul>\n\n<p>For the full year 2024, Blueprint Medicines reported:</p>\n<ul>\n<li>Revenue: $508.8 million, including $479.0 million in net product revenue from its lead drug AYVAKIT/AYVAKYT.</li>\n<li>Net Loss: $67.1 million, or $(1.07) per share.</li>\n</ul>\n\n<p>The company provided guidance for 2025, anticipating global AYVAKIT net product revenue of approximately $680 million to $710 million, representing 45% year-over-year growth at the midpoint.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BPMC","symbol_name":"Blueprint Medicines Corporation","start_time":0,"source_url":"","article_id":"1140978482","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140978482","pubTimestamp":1739457447,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Blueprint Medicines Corp.  saw its stock plummet 8.27% in pre-market trading on Thursday, after the company reported its fourth-quarter and full-year 2024 financial results.The biopharmaceutical company, focused on developing treatments for cancer and rare diseases, reported mixed results for the quarter:. Earnings: Q4 GAAP EPS of $ missed the analyst consensus estimate of $ by 12.86%.Revenue: Q4 revenue of $146.37 million beat the analyst consensus estimate of $145.84 million by 0.36%. This rep","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BPMC":"Blueprint Medicines Corporation"},"translate_title":"股票轨迹Blueprint Medicines暴跌8.27%，第四季度盈利未达预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BPMC":1},"content_text":"Blueprint Medicines Corp. (BPMC) saw its stock plummet 8.27% in pre-market trading on Thursday, after the company reported its fourth-quarter and full-year 2024 financial results.\nThe biopharmaceutical company, focused on developing treatments for cancer and rare diseases, reported mixed results for the quarter:\n\nEarnings: Q4 GAAP EPS of $(0.79) missed the analyst consensus estimate of $(0.70) by 12.86%.\nRevenue: Q4 revenue of $146.37 million beat the analyst consensus estimate of $145.84 million by 0.36%. This represented a 103.41% increase from the same period last year.\n\nFor the full year 2024, Blueprint Medicines reported:\n\nRevenue: $508.8 million, including $479.0 million in net product revenue from its lead drug AYVAKIT/AYVAKYT.\nNet Loss: $67.1 million, or $(1.07) per share.\n\nThe company provided guidance for 2025, anticipating global AYVAKIT net product revenue of approximately $680 million to $710 million, representing 45% year-over-year growth at the midpoint.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}